AbbVie Touts Long-Term Efficacy of Qulipta as Preventive Migraine Treatment

AbbVie on Friday released interim Phase III data for its calcitonin gene-related peptide receptor blocker Qulipta (atogepant), which demonstrated long-term safety and efficacy for patients in preventing chronic and episodic migraine.